Phase I Study of SGN-CD228A in Select Advanced Solid Tumors
Summary
The purpose of this phase I study of SGN-CD228A is to find out whether it is an effective treatment for different kinds of cancer. It will also look at what side effects (unwanted effects) may occur. The study will have two parts. Part 1 of the study will find out how much SGN-CD228A should be given for treatment and how often. Part 2 of the study will use the dose found in Part 1 and look at how safe and effective the treatment is.
General Information
NCT#: NCT04042480
Study ID: SGN228-001
Trial Phase: Phase I
Trial Sponsor: Seattle Genetics, Inc.
Therapies Used in This Trial: SGN-CD228A